BLI-1005

N/A

Report date: 2023/02/01 18:00:08

Base Information

Drug NameBLI-1005
Drug Alias NameABV-1504BLI-1005PDC-1421ABV-1505ABV-1601
ClassificationNatural product/Extract
Mechanisms of ActionNorepinephrine transporter inhibitors
TargetsNorepinephrine transporter
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityDepressive Disorder, Major
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedical And Pharmaceutical Industry Technology And Development Center
China Registration ClassN/A

Develop Information

Active CompaniesXinnovation Therapeutics Co LtdAibtl Biopharma IncAbvc BioPharma Inc +[4] 
Inactive CompaniesN/A
Active IndicationsAttention Deficit Disorder with HyperactivityDepressive Disorder, Major
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A